Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed. This update does not modify the study details, eligibility criteria, endpoints, or other substantive content on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRemoved the government funding/operating-status notice at the top of the page; no core study data or critical content were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedThe study details page shows no significant updates; core information including eligibility criteria and primary outcomes appears unchanged.SummaryDifference0.4%

- Check62 days agoChange DetectedVersion bump to v3.2.0 accompanied by a government-operating-status notice; replaces the earlier v3.1.0 tag.SummaryDifference3%

- Check69 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.2%

- Check83 days agoChange DetectedRevision: v3.0.2 is now displayed, replacing v3.0.1, and the Back to Top element was removed; this is a minor update with no changes to core content, pricing, stock availability, or time slot information.SummaryDifference0.2%

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.